Organization
Soonchunhyang University Seoul Hospital
1 abstract
Abstract
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18.Org: Gangneung Asan Hospital, Yeungnam University Medical Center, Ilslan Paik Hospital, Center for Lung Cancer, Soonchunhyang University Seoul Hospital,